Jos H. Beijnen
Clinical Cancer Research · 2000–2012
A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Whom Jos H. Beijnen trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Jos H. Beijnen's perspective
Ordered by how strongly the researchers Jos H. Beijnen trusts endorse each paper. Same corpus, a different order for every researcher.
- Potent antibody therapeutics by design (Nature reviews. Immunology)
- Antibody pharmacokinetics and pharmacodynamics. (Journal of Pharmacy and Science)
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
- Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. (New England Journal of Medicine)
- Comparing antibody and small-molecule therapies for cancer (Nature Reviews. Cancer)
- Production of recombinant protein therapeutics in cultivated mammalian cells (Nature Biotechnology)
- The Hypercycle: A principle of natural self-organization
- Monoclonal antibody successes in the clinic (Nature Biotechnology)
- Engineered antibody Fc variants with enhanced effector function.
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Their papers
- Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. (2000) — 682 citations
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. (2012) — 701 citations
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM (2011) — 333 citations
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies (2010) — 690 citations
- A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent (2004) — 704 citations